-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Mecobalamin Injection Has Been Approved Following Consistency Evaluation
Category:
发布时间：2022-09-13
【概要描述】
Recently, methylcobalamin injection (1 ml: 0.5 mg) developed by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and has passed the evaluation of quality and therapeutic equivalence for generic drugs.
Recently, methylcobalamin injection (1 ml: 0.5 mg) developed by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and has passed the evaluation of quality and therapeutic equivalence for generic drugs.
According to reports, mecobalamin injection is primarily used to treat peripheral neuropathy and megaloblastic anemia caused by vitamin B12 deficiency.
Over the past two years, Shijiazhuang Sihua Pharmaceutical has pursued a coordinated and sustained effort in the development of innovative drugs, generic drugs, and active pharmaceutical ingredients, as well as in consistency evaluation studies, yielding substantial and steadily accumulating innovation achievements. To date, a total of 28 drug varieties comprising 37 dosage forms under the Shijiazhuang Sihua Pharmaceutical Group have either passed or been deemed to have passed the National Generic Drug Quality and Therapeutic Equivalence Evaluation, placing the company at the forefront of the industry in terms of both the number of approvals and the pace of progress.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091